

Iowa Medicaid Drug Utilization Review (DUR) Commission

August 2, 2023

**Location: Grimes State Office Building Room B100
400 E 14th Street
Des Moines, IA 50319**

Time: 9:30 a.m. – 1:30 p.m. CT

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the May 3, 2023 Meeting Minutes
 - b) May 2023 DUR Recommendation Letter to DHHS
 - c) Annual Chair and Vice Chair Elections
 - d) Annual Conflict of Interest Disclosure
 - e) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
 - a) Iowa Total Care
 - b) Fee-for-Service
 - c) Amerigroup
 - d) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - **Verbal** - Must sign up morning of meeting to provide verbal public comment and complete a conflict of interest disclosure. Five (5) minute maximum limit.
 - **Written** - Submissions must be received no later than **4:30 p.m. CT July 26, 2023**. Send to info@iadur.org
 - Reference complete public comment policy [here](#).
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Antidepressants in Children
 - ii. Metabolic Monitoring in Children and Adolescents on Antipsychotics
 - b) Proposal(s)
 - i. Antianxiety/Sedatives in Children
 - ii. Mood Stabilizers in Children
 - c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Prospective DUR

- a) Seizure Rescue Treatment, Nasal Spray - Quantity Limit – Initial Review
- 8. Break (10 minutes)
- 9. Prior Authorization
 - a) Antidepressants – Initial Review
 - b) Deucravacitinib (Sotyktu) – Initial Review
 - c) Tezepelumab (Tezspire) – Initial Review
 - d) Janus Kinase Inhibitors – Initial Review
 - e) Palivizumab (Synagis) – Second Review
 - f) Naloxone Nasal Spray – Second Review
 - g) IL-5 Antagonists – Second Review
 - h) Select Anticonvulsants – Second Review
 - i) Cyclosporine Ophthalmic Emulsion (Verkazia) – Second Review
 - j) Clascoterone (Winlevi) – Second Review

10. Miscellaneous

- a) DUR Digest Vol. 35, No. 2 – Second Review
- b) MedWatch

[FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions](#)

[FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease](#)

[FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause](#)

[FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa](#)

[FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose](#)

[FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder](#)

[FDA approves first treatment for pediatric functional constipation](#)

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131.

Next Meeting
November 1, 2023
Grimes State Office Building Room B100
400 E 14th St., Des Moines, IA 50319